Literature DB >> 10372074

Assessing otolith function by the subjective visual vertical.

A Böhmer1, F Mast.   

Abstract

The effects of peripheral vestibular diseases on the subjective visual vertical (SVV) are resumed and provide the basis for some insights into the otolith pathophysiology. With a normal range of 0 +/- 2 deg (when measured in an upright body position), the SVV was shifted by 11 +/- 6 deg toward the ipsilateral ear in 40 patients following an acute unilateral vestibular deafferentiation (UVD), but in the opposite direction in 9 of 52 patients after stapes surgery. These opposite effects suggest a push-pull mechanism of the pairs of otolith organs with respect to the SVV. The dissociation between the SVV and the perception of body position indicates influences by unconscious reflexive mechanisms such as ocular cyclotorsion on the SVV. In chronic UVD patients, lateral shifts of the subjects during constant angular velocity rotation into various eccentric positions (+/- 16 cm) revealed a shift of the "center of graviception" close to the remaining intact contralateral inner ear. To date, this seems to be the most consistent test for clinical identification of a chronic compensated unilateral loss of otolith function. The findings regarding asymmetries in otolithic sensitivity to medially and laterally directed roll-tilts remain controversial, probably mainly because of influences of extravestibular cues.

Entities:  

Mesh:

Year:  1999        PMID: 10372074     DOI: 10.1111/j.1749-6632.1999.tb09187.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

1.  Direction specific error patterns during continuous tracking of the subjective visual vertical.

Authors:  S Keusch; B J M Hess; K Jaggi-Schwarz
Journal:  Exp Brain Res       Date:  2004-01-15       Impact factor: 1.972

2.  Effects of galvanic vestibular stimulation on human posture and perception while standing.

Authors:  Daniel L Wardman; Janet L Taylor; Richard C Fitzpatrick
Journal:  J Physiol       Date:  2003-07-15       Impact factor: 5.182

3.  Subjective visual vertical (SVV) determined in a representative sample of 15 patients with pusher syndrome.

Authors:  Leif Johannsen; Monika Fruhmann Berger; Hans-Otto Karnath
Journal:  J Neurol       Date:  2006-06-20       Impact factor: 4.849

4.  Localization of the subjective vertical during roll, pitch, and recumbent yaw body tilt.

Authors:  Simone B Bortolami; Alberto Pierobon; Paul DiZio; James R Lackner
Journal:  Exp Brain Res       Date:  2006-04-21       Impact factor: 1.972

5.  Mental transformation abilities in patients with unilateral and bilateral vestibular loss.

Authors:  Luzia Grabherr; Cyril Cuffel; Jean-Philippe Guyot; Fred W Mast
Journal:  Exp Brain Res       Date:  2011-02-02       Impact factor: 1.972

6.  One step closer to a functional vestibular prosthesis.

Authors:  Chris J Dakin; L Caitlin Elmore; Ari Rosenberg
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

7.  [Measuring the subjective visual vertical using a portable system: a comparison with the standard darkroom method].

Authors:  B Eghlimi; H Schaaf; G Hesse
Journal:  HNO       Date:  2012-04       Impact factor: 1.284

8.  Interaction of somatoform and vestibular disorders.

Authors:  C Best; A Eckhardt-Henn; G Diener; S Bense; P Breuer; M Dieterich
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

9.  Test-retest reliability of subjective visual vertical measurements with lateral head tilt in virtual reality goggles.

Authors:  Chia-Han Wang; Ariel A Winnick; Yu-Hung Ko; Zheyu Wang; Tzu-Pu Chang
Journal:  Tzu Chi Med J       Date:  2021-01-19

10.  A new method to analyze the subjective visual vertical in patients with bilateral vestibular dysfunction.

Authors:  Martha Funabashi; Taiza Elaine Grespan Santos-Pontelli; José Fernando Colafêmina; Theo Zeferino Pavan; Antonio Adilton Oliveira Carneiro; Osvaldo Massaiti Takayanagui
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.